Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

BACKGROUND: We performed a multicenter, double-blind, placebo-controlled, phase II clinical trial of human dsDNA-based preparation Panagen in a tablet form. In total, 80 female patients with stage II-IV breast cancer were recruited. METHODS: Patients received three consecutive FAC (5-fluorouracil, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Proskurina, Anastasia S, Gvozdeva, Tatiana S, Alyamkina, Ekaterina A, Dolgova, Evgenia V, Orishchenko, Konstantin E, Nikolin, Valeriy P, Popova, Nelly A, Sidorov, Sergey V, Chernykh, Elena R, Ostanin, Alexandr A, Leplina, Olga Y, Dvornichenko, Victoria V, Ponomarenko, Dmitriy M, Soldatova, Galina S, Varaksin, Nikolay A, Ryabicheva, Tatiana G, Zagrebelniy, Stanislav N, Rogachev, Vladimir A, Bogachev, Sergey S, Shurdov, Mikhail A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365563/
https://www.ncbi.nlm.nih.gov/pubmed/25886605
http://dx.doi.org/10.1186/s12885-015-1142-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365563/
https://www.ncbi.nlm.nih.gov/pubmed/25886605
http://dx.doi.org/10.1186/s12885-015-1142-z

Ejemplares similares